A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
Cationic nanogel
Nasal vaccine
Non-human primate
Pneumonia
PspA
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
19
01
2021
revised:
20
04
2021
accepted:
30
04
2021
pubmed:
22
5
2021
medline:
9
7
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
Current polysaccharide-based pneumococcal vaccines are effective but not compatible with all serotypes of Streptococcus pneumoniae. We previously developed an adjuvant-free cationic nanogel nasal vaccine containing pneumococcal surface protein A (PspA), which is expressed on the surfaces of all pneumococcal serotypes. Here, to address the sequence diversity of PspA proteins, we formulated a cationic nanogel-based trivalent pneumococcal nasal vaccine and demonstrated the vaccine's immunogenicity and protective efficacy in macaques by using a newly developed nasal spray device applicable to humans. Nasal vaccination of macaques with cationic cholesteryl pullulan nanogel (cCHP)-trivalent PspA vaccine effectively induced PspA-specific IgGs that bound to pneumococcal surfaces and triggered complement C3 deposition. The immunized macaques were protected from pneumococcal intratracheal challenge through both inhibition of lung inflammation and a dramatic reduction in the numbers of bacteria in the lungs. These results demonstrated that the cCHP-trivalent PspA vaccine is an effective candidate vaccine against pneumococcal infections.
Identifiants
pubmed: 34016473
pii: S0264-410X(21)00552-1
doi: 10.1016/j.vaccine.2021.04.069
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Bacterial Proteins
0
Nanogels
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3353-3364Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yuki Y. and Hiroshi K. are directors and founders of HanaVax Inc. Nakahashi-Ouchida R., Sawada S., and Akiyoshi K. are scientific advisors of HanaVax Inc. The remaining authors declare no competing interests].